Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Edoxaban Versus Apixaban in Cancer-Associated Venous Thromboembolism (NEXT-CAT)

25. září 2026 aktualizováno: Eun Kyoung Kim, Samsung Medical Center

Net Adverse Clinical Events With EdoXaban Versus Apixaban Treatment in Cancer-Associated Thrombosis

This prospective, multicenter, randomized, open-label, blinded-endpoint trial aims to compare the clinical efficacy and safety of edoxaban-based treatment versus apixaban-based treatment in patients with cancer-associated venous thromboembolism (CAT). A total of 2,300 patients with active cancer and objectively confirmed venous thromboembolism will be randomized in a 1:1 ratio to receive edoxaban-based or apixaban-based treatment. The primary objective is to determine whether edoxaban-based treatment is non-inferior to apixaban-based treatment with respect to net adverse clinical events (NACE), defined as a composite of recurrent venous thromboembolism, venous thromboembolism-related death, or major bleeding according to the International Society on Thrombosis and Haemostasis criteria.

Přehled studie

Postavení

Zatím nenabíráme

Podmínky

Intervence / Léčba

Detailní popis

Cancer-associated thrombosis (CAT) is an important cause of morbidity and mortality in patients with active cancer. Patients with CAT are at increased risk of both recurrent venous thromboembolism and bleeding during anticoagulant treatment, making the balance between efficacy and safety particularly important when selecting an anticoagulant.

Non-vitamin K antagonist oral anticoagulants have become established treatment options for CAT. Edoxaban and apixaban are both factor Xa inhibitors with demonstrated efficacy and safety in patients with CAT. However, they have been evaluated separately against low-molecular-weight heparin, and direct randomized comparisons between edoxaban and apixaban are lacking. The two agents also differ in dosing frequency, dose-reduction strategies, pharmacokinetic characteristics, and renal elimination. Whether these differences translate into differences in overall clinical outcomes in patients with CAT remains uncertain.

NEXT-CAT is a prospective, multicenter, randomized, open-label, blinded-endpoint trial designed to directly compare edoxaban-based treatment with apixaban-based treatment in patients with active cancer and objectively confirmed venous thromboembolism. A total of 2,300 participants will be randomized in a 1:1 ratio, with randomization stratified by participating center and the presence of gastrointestinal cancer at baseline.

The primary hypothesis is that edoxaban-based treatment is non-inferior to apixaban-based treatment with respect to the incidence of net adverse clinical events (NACE). The primary endpoint is a composite of recurrent venous thromboembolism, venous thromboembolism-related death, or major bleeding according to the International Society on Thrombosis and Haemostasis criteria. Participants will be followed at 1, 3, 6, 9, 12, and 18 months after randomization and annually thereafter, with follow-up continuing until 1 year after enrollment of the last participant.

Clinical events corresponding to the primary and secondary endpoints will be evaluated by an independent Clinical Event Adjudication Committee blinded to treatment allocation.

Typ studie

Intervenční

Zápis (Odhadovaný)

2300

Fáze

  • Fáze 4

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní kontakt

Studijní místa

      • Busan, Jižní Korea
        • Dong-A University Hospital
        • Kontakt:
          • Sung-Hyun Kim
        • Vrchní vyšetřovatel:
          • Sung-Hyun Kim, MD, PhD
      • Goyang, Jižní Korea
        • Inje University Ilsan Paik Hospital
        • Kontakt:
          • Min Sun Kim
        • Vrchní vyšetřovatel:
          • Min Sun Kim
      • Gwangmyeong, Jižní Korea
        • Chung-Ang University Gwangmyeong Hospital
        • Kontakt:
          • Eun Jeong Cho
        • Vrchní vyšetřovatel:
          • Eun Jeong Cho
      • Hwasun, Jižní Korea
        • Chonnam National University Hwasun Hospital
        • Kontakt:
          • Hyukjin Park
        • Vrchní vyšetřovatel:
          • Hyukjin Park
      • Jeonju, Jižní Korea
        • Chonbuk National University Hospital
        • Kontakt:
          • Ho-Young Yhim
        • Vrchní vyšetřovatel:
          • Ho-Young Yhim, MD, PhD
      • Seoul, Jižní Korea
        • Kangbuk Samsung Hospital
        • Kontakt:
          • Jiwon Kim
        • Vrchní vyšetřovatel:
          • Jiwon Kim
      • Seoul, Jižní Korea
        • Korea University Anam Hospital
        • Kontakt:
          • So Ree Kim
        • Vrchní vyšetřovatel:
          • So Ree Kim
      • Seoul, Jižní Korea
        • Samsung Medical Center
        • Dílčí vyšetřovatel:
          • Se-Hoon Lee, MD, PhD
        • Dílčí vyšetřovatel:
          • Taek Kyu Park, MD, PhD
        • Kontakt:
        • Vrchní vyšetřovatel:
          • Eun Kyoung Kim, MD, PhD
        • Dílčí vyšetřovatel:
          • David Hong, MD, PhD
      • Seoul, Jižní Korea
        • Seoul National University Hospital
        • Kontakt:
          • Sang-Hoon Na, MD, PhD
        • Vrchní vyšetřovatel:
          • Sang-Hoon Na, MD, PhD
      • Seoul, Jižní Korea
        • Konkuk University Medical Center
        • Kontakt:
          • Ji-Won Hwang
        • Vrchní vyšetřovatel:
          • Ji-Won Hwang
      • Seoul, Jižní Korea
        • Seoul St. Mary's Hospital
        • Kontakt:
          • Mi-Hyang Jung
        • Vrchní vyšetřovatel:
          • Mi-Hyang Jung, MD, PhD
    • Gyeonggi-do
      • Goyang-si, Gyeonggi-do, Jižní Korea
        • National Cancer Center
        • Kontakt:
          • Mi-Hyang Kwak
        • Vrchní vyšetřovatel:
          • Mi-Hyang Kwak

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

19 let a starší (Dospělý, Starší dospělý)

Přijímá zdravé dobrovolníky

Ne

Pohlaví způsobilá ke studiu

Všechno

Popis

Inclusion Criteria:

  1. Age ≥19 years.

  2. Objectively confirmed symptomatic or incidentally detected venous thromboembolism (VTE), including:

    • Proximal deep vein thrombosis (DVT)
    • Pulmonary embolism (PE)
    • Both DVT and PE.
  3. Any type of active cancer, defined by at least one of the following:

    • Cancer diagnosed within the previous 6 months
    • Locally advanced or metastatic cancer
    • Receipt of cancer-directed therapy (chemotherapy, immunotherapy, targeted therapy, endocrine therapy, radiotherapy, or cancer surgery) within the previous 6 months
    • Cancer not in complete remission at the time of enrollment
    • Ongoing cancer treatment or residual cancer.
  4. Ability to understand the risks, benefits, and treatment alternatives of the study and to voluntarily provide written informed consent.

Exclusion Criteria:

  1. Known hypersensitivity or contraindication to either study drug (edoxaban or apixaban).
  2. Severe renal impairment (creatinine clearance <15 mL/min) or dialysis.
  3. Active major bleeding.
  4. An indication requiring alternative anticoagulation, such as a mechanical heart valve or moderate-to-severe mitral stenosis.
  5. Antiphospholipid syndrome.
  6. Life expectancy <6 months due to cancer progression or comorbid conditions, or anticipated poor treatment adherence, as determined by the investigator.
  7. Pregnancy or breastfeeding.
  8. Moderate or severe hepatic impairment classified as Child-Pugh class B or C.
  9. Thrombocytopenia with a platelet count <50,000/mm³.

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Léčba
  • Přidělení: Randomizované
  • Intervenční model: Paralelní přiřazení
  • Maskování: Singl

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Aktivní komparátor: Edoxaban-based Treatment

Participants randomized to this arm will receive oral edoxaban once daily. The standard dose is 60 mg once daily, with dose reduction according to the protocol based on renal function, body weight, concomitant P-glycoprotein inhibitors, and other prespecified clinical factors.

Edoxaban is administered orally once daily. The standard dose is 60 mg once daily. The dose is reduced to 30 mg once daily in participants with a creatinine clearance of 15-50 mL/min, body weight ≤60 kg, or concomitant use of specified P-glycoprotein inhibitors. In participants aged ≥80 years who are considered at high risk of bleeding and meet the prespecified criteria, further dose reduction to 15 mg once daily may be considered.

Aktivní komparátor: Apixaban-based Treatment

Participants randomized to this arm will receive oral apixaban twice daily. The standard dose is 5 mg twice daily, with dose reduction to 2.5 mg twice daily according to the prespecified dose-reduction criteria in the protocol.

Apixaban is administered orally at a standard dose of 5 mg twice daily. The dose is reduced to 2.5 mg twice daily in participants who meet the prespecified dose-reduction criteria, including those who meet at least two of the following criteria: age ≥80 years, body weight ≤60 kg, or serum creatinine ≥1.5 mg/dL, or those with severe renal impairment with a creatinine clearance of 15-29 mL/min.

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Net Adverse Clinical Events (NACE)
Časové okno: From randomization until 1 year after enrollment of the last participant

Time to the first occurrence of a net adverse clinical event, defined as a composite of recurrent venous thromboembolism, venous thromboembolism-related death, or major bleeding according to the International Society on Thrombosis and Haemostasis (ISTH) criteria.

From randomization until 1 year after enrollment of the last participant

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Recurrent Venous Thromboembolism or Venous Thromboembolism-related Death
Časové okno: From randomization until 1 year after enrollment of the last participant

Time to the first occurrence of recurrent venous thromboembolism or venous thromboembolism-related death.

From randomization until 1 year after enrollment of the last participant
Recurrent Venous Thromboembolism
Časové okno: From randomization until 1 year after enrollment of the last participant

Time to the first occurrence of objectively confirmed recurrent venous thromboembolism, including recurrent deep vein thrombosis or recurrent pulmonary embolism.

From randomization until 1 year after enrollment of the last participant
Venous Thromboembolism-related Death
Časové okno: From randomization until 1 year after enrollment of the last participant

Death resulting from objectively confirmed fatal pulmonary embolism, recurrent venous thromboembolism directly leading to death, or unexplained death for which no alternative cause is identified and which is adjudicated as venous thromboembolism-related by the Clinical Event Adjudication Committee.

From randomization until 1 year after enrollment of the last participant
Major Bleeding According to International Society on Thrombosis and Haemostasis Criteria
Časové okno: From randomization until 1 year after enrollment of the last participant

Time to the first occurrence of major bleeding according to International Society on Thrombosis and Haemostasis criteria, including fatal bleeding, symptomatic bleeding in a critical area or organ, bleeding causing a decrease in hemoglobin of at least 2 g/dL, or bleeding requiring transfusion of at least 2 units of whole blood or packed red blood cells.

From randomization until 1 year after enrollment of the last participant
Clinically Relevant Non-major Bleeding
Časové okno: From randomization until 1 year after enrollment of the last participant

Time to the first occurrence of clinically relevant non-major bleeding, defined as clinically overt bleeding that does not meet the criteria for major bleeding but leads to hospitalization or an increased level of care, medical or surgical treatment, or a change in antithrombotic therapy.

From randomization until 1 year after enrollment of the last participant
Clinically Relevant Bleeding
Časové okno: From randomization until 1 year after enrollment of the last participant

Time to the first occurrence of clinically relevant bleeding, defined as a composite of major bleeding or clinically relevant non-major bleeding.

From randomization until 1 year after enrollment of the last participant
Broad Net Adverse Clinical Events
Časové okno: From randomization until 1 year after enrollment of the last participant

Time to the first occurrence of a broad net adverse clinical event, defined as a composite of recurrent venous thromboembolism, venous thromboembolism-related death, major bleeding, or clinically relevant non-major bleeding.

From randomization until 1 year after enrollment of the last participant
All-cause Mortality
Časové okno: From randomization until 1 year after enrollment of the last participant

Death due to any cause occurring during the study follow-up period.

From randomization until 1 year after enrollment of the last participant
Permanent Discontinuation Due to Adverse Events
Časové okno: From randomization until 1 year after enrollment of the last participant

Permanent discontinuation of the assigned study drug due to any adverse event during follow-up.

From randomization until 1 year after enrollment of the last participant

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Sponzor

Spolupracovníci

Vyšetřovatelé

  • Vrchní vyšetřovatel: Eun Kyoung Kim, Samsung Medical Center

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Odhadovaný)

1. listopadu 2026

Primární dokončení (Odhadovaný)

31. prosince 2029

Dokončení studie (Odhadovaný)

31. prosince 2030

Termíny zápisu do studia

První předloženo

25. září 2026

První předloženo, které splnilo kritéria kontroly kvality

25. září 2026

První zveřejněno (Aktuální)

1. října 2026

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

1. října 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

25. září 2026

Naposledy ověřeno

1. září 2026

Více informací

Termíny související s touto studií

Další identifikační čísla studie

  • 2026-07-044

Plán pro data jednotlivých účastníků (IPD)

Plánujete sdílet data jednotlivých účastníků (IPD)?

ANO

Popis plánu IPD

De-identified individual participant data that underlie the results reported in the main publication may be shared with qualified researchers upon reasonable request.

Časový rámec sdílení IPD

Beginning after publication of the main study results; no predetermined end date.

Kritéria přístupu pro sdílení IPD

Data may be made available to qualified researchers upon reasonable request for scientifically appropriate research purposes. Requests will be reviewed by the principal investigator and the study steering committee based on the scientific merit and appropriateness of the proposed research and data-use plan. Data sharing will be conducted in accordance with applicable regulations and participant privacy requirements.

Typ podpůrných informací pro sdílení IPD

  • PROTOKOL STUDY
  • MÍZA

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ne

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .